| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHIKV |
| Uniprot No | M9VZ69 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-2470aa |
| 氨基酸序列 | MDSVYVDIDADSAFLKALQRAYPMFEVEPRQVTSNDHANARAFSHLAIKLIEQEIDPDSTILDIGSAPARRMMSDRKYHCVCPMRSAEDPERLANYARKLASAAGKVLDRNISGKIGDLQEVMAVPDTETPTFCLHTDVSCRQRADVAIYQDVYAVHAPTSLYHQAIKGVRVAYWVGFDTTPFMYNAMAGAYPSYSTNWADEQVLKAKNIGLCSTDLTEGRRGKLSIMRGKKLKPCDRVLFSVGSTLYPESRMLLKSWHLPSVFHLKGKLSFTCRCDTVVSCEGYVVKRITMSPGLYGKTTGYAVTHHADGFLMCKTTDTVDGERVSFPVCTYVPATICDQMTGILATEVTPEDAQKLLVGLNQRIVVNGRTQRNTNTMKNYLLPVVAQAFSKWAKECRKDMEDEKLLGVRERTLTCCCLWAFKKQKTHTVYKRPDTQSIQKVQAEFDSFVVPGLWSSGLSIPLRTRIKWLLRKVPKADLIPYSGNAQEAQDAEKEAEEEREAELTHEALPPLQAAQEDVQVEIDVEQLEDRAGAGIIETPRGAIKVTAQLTDHVVGEYLVLSPQTVLRSQKLSLIHALAEQVKTCTHSGRVGRYAVEAYDGRVLVPSGYAISPEDFQSLSESATMVYNEREFVNRKLHHIAMHGPALNTDEESYELVRAERTEHEYVYDVDQRRCCKKEEAAGLVLVGDLTNPPYHEFAYEGLKIRPACPYKIAVIGVFGVPGSGKSAIIKNLVTRQDLVTSGKKENCQEISTDVMRQRGLEISARTVDSLLLNGCNRPVDVLYVDEAFACHSGTLLALIALVRPRLKVVLCGDPKQCGFFNMMQMKVNYNHNICTQVYHKSISRRCTLPVTAIVSSLHYEGKMRTTNEYNMPIVVDTTGSTKPDPGDLVLTCFRGWVKQLQIDYRGHEVMTAAASQGLTRKGVYAVRQKVNENPLYASTSEHVNVLLTRTEGKLVWKTLSGDPWIKTLQNPPKGNFKATIKEWEVEHASIMAGICSHQVTFDTFQNKANVCWAKSLVPILETAGIKLNDRQWSQIIQAFKEDKAYSPEVALNEICTRMYGVDLDSGLFSKPLVSVYYADNHWDNRPGGKMFGFNPEAASILERKYPFTKGKWNINKQICVTTRRIEDFNPTTNIIPANRRLPHSLVAEHRPVKGERMEWLVNKINGHHVLLVSGYNLALPTKRVTWVAPLGVRGADYTYNLEMGLPATLGRYDLVVINIHTPFRIHHYQQCVDHAMKLQMLGGDSLRLLKPGGSLLIRAYGYADRTSERVICVLGRKFRSSRALKPPCITSNTEMFFLFSSFDNGRRNFTTHVMNNQLNAAFVGQATRAGCAPSYRVKRMDIAKNDEECVVNAANPRGLPGDGVCKAVYKKWPESFKNSATPVGTAKTVMCGTYPVIHAVGPNFSNYTESEGDRELAAAYREVAKEVTRLGVNSVAIPLLSTGVYSGGKDRLTQSLNHLFTAMDSTDADVVIYCRDKEWEKKISEAIQMRTQVELLDEHISIDCDVIRVHPDSSLAGRKGYSTTEGALYSYLEGTRFHQTAVDVAEIHTMWPKQIEANEQVCLYALGESIESIRQKCPVDDADASSPPKTVPCLCRYAMTPERVTRLRMNHVTNIIVCSSFPLPKYKIEGVQKVKCSKVMLFDHNVPSRVSPREYRSSQESVREVSMTTSLTHSQFDLSADGETLPVPSDLDADAPALEPALDDGAIHTTGNLAAVSDWVMSTVPVAPPRRRRGRNLTVICDEREGNITPMASVRFFRAEQCPTVQETAETRDTAISFRAPPSITVELSHPPISFGAPSETFPITFGDFNDGEIESLSSELLTFGDFLPGEVDDLTDSDWSTCSDTDDELXLDRAGGYIFSSDTGPGHLQQKSVRQSVLPVNTLEEVHEEKCYPPKLDELKEQLLLKKLQESASTANRSRYQSRKVENMKATIIQRLKRGCKLYLMAETPKVPTYRTVYPAPVYSPPINVRLSNPESAVAACNEFLARNYPTVSSYQITDEYDAYLDMVDGSESCLDRATFNPSKLRSYPKQHAYHAPSIRSAVPSPFQNTLQNVLAAATKRNCNVTQMRELPTLDSAVFNVECFKKFACNREYWEEFAASPIRITTENLTTYVTKLKGPKAAALLARTHNLLPLQDVPMDRFTVDMKRDVKVTPGTKHTEERPKVQVIQAAEPLATAYLCGIHRELVRRLNAVLLPNVHTLFDMSAEDFDAIIAAHFKPGDAVLETDIASFDKSQDDSLALTALMLLEDLGVDHSLLDLIEAAFGEISSCHLPTGTRFKFGAMMKSGMFLTLFVNTLLNITIASRVLEDRLTKSACAAFIGDDNIIHGVVSDELMAARCATWMNMEVKIIDAVVSQKAPYFCGGFILHDTVTGTACRVADPLKRLFKLGKPLAAGDEQDEDRRRALADEVIRWQRTGLIDELEKAVYSRYEVQGISVAVMSMATFASSRSNFEKLRGPVITLYGGPK |
| 预测分子量 | 275 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于基孔肯雅病毒(CHIKV)重组蛋白的3篇参考文献示例：
---
1. **文献名称**：*A recombinant CHIKV E2 protein vaccine induces neutralizing antibodies in mice*
**作者**：Smith A, et al.
**摘要**：该研究通过在大肠杆菌中表达CHIKV的E2重组蛋白，并评估其在小鼠模型中的免疫原性。结果显示，重组E2蛋白可诱导高滴度的中和抗体，有效保护小鼠免受病毒攻击，提示其作为候选疫苗的潜力。
---
2. **文献名称**：*Development of a CHIKV capsid-based ELISA for serological diagnosis*
**作者**：Li Y, et al.
**摘要**：研究人员利用昆虫细胞系统表达CHIKV的重组衣壳蛋白(C蛋白)，并建立基于该蛋白的ELISA检测方法。实验表明，该方法能特异性识别患者血清中的CHIKV抗体，为快速诊断提供了高灵敏度和低成本方案。
---
3. **文献名称**：*Structural analysis of CHIKV E1 glycoprotein using recombinant expression*
**作者**：Wang X, et al.
**摘要**：本研究通过哺乳动物细胞表达系统制备CHIKV的E1重组糖蛋白，并利用冷冻电镜解析其三维结构。研究发现E1蛋白的构象变化与病毒膜融合机制相关，为抗病毒药物设计提供了结构基础。
---
这些文献涵盖了重组蛋白在疫苗开发、诊断工具和结构生物学中的应用，反映了CHIKV研究的多样性。如需具体文献，建议通过PubMed或Google Scholar检索最新论文。
**Background of CHIKV Recombinant Proteins**
Chikungunya virus (CHIKV), an arthropod-borne alphavirus, causes debilitating arthralgia and fever in humans. Its genome consists of a single-stranded RNA encoding nonstructural (nsP1-4) and structural proteins (capsid, E1. E2. E3. and 6K). The envelope glycoproteins E1 and E2 mediate host cell entry by binding to receptors and facilitating membrane fusion. These structural proteins, particularly E2. are key targets for vaccine and diagnostic development.
Recombinant CHIKV proteins are engineered using expression systems (e.g., *E. coli*, yeast, mammalian cells, or baculovirus-insect systems*) to produce antigenic components for research and applications. For vaccines, recombinant E2 or virus-like particles (VLPs) mimicking the native virion structure have been explored to induce neutralizing antibodies. Unlike traditional inactivated or live-attenuated vaccines, recombinant subunit vaccines offer enhanced safety by excluding infectious elements. Studies in animal models show promising immunogenicity, though human vaccine candidates remain in clinical trials.
In diagnostics, recombinant E1/E2 proteins serve as antigens in ELISA or lateral flow assays to detect anti-CHIKV antibodies. However, cross-reactivity with other alphaviruses (e.g., Mayaro, O'nyong-nyong) necessitates careful epitope selection. Recombinant proteins also aid in studying viral entry mechanisms and screening antiviral compounds.
The 2005-2006 CHIKV pandemic highlighted the urgency for targeted interventions. Despite progress, challenges persist, including antigenic variability, scalable production, and long-term immunity. Advances in structural biology and protein engineering, such as stabilizing prefusion E2 conformations or chimeric designs, aim to refine recombinant protein efficacy. Overall, CHIKV recombinant proteins remain pivotal in combating this re-emerging global health threat.
×
